Sleep Intervention for Suicidal Behavior
(TAILOR Trial)
Trial Summary
The trial does not specify if you need to stop taking your current medications. However, if you have had a change in antipsychotic or mood stabilizer medications in the last 2 months, you may not be eligible to participate.
Research shows that sleep disturbances are linked to suicidal thoughts and behaviors in adolescents. Addressing sleep issues, such as insomnia, during treatment may help reduce the risk of suicidal behavior.
12345The research suggests that managing sleep disturbances, such as insomnia and nightmares, is important for reducing suicide risk, but it does not provide specific safety data for the sleep intervention itself. However, therapeutic approaches like cognitive behavior therapy for insomnia and imagery rehearsal treatment are generally considered safe and show promise in treating sleep disorders and suicidal behavior.
15678The TAILOR treatment is unique because it specifically targets sleep disturbances, such as insomnia, which are linked to suicidal thoughts and behaviors in adolescents. By focusing on improving sleep, this treatment aims to reduce the risk of suicide, which is a novel approach compared to traditional methods that may not address sleep issues directly.
12457Eligibility Criteria
This trial is for adolescents aged 11-18 who are patients at Nationwide Children's Hospital, have had suicidal thoughts and sleep problems recently, and live with a caregiver who can consent to research. It excludes those with certain sleep disorders, recent substance use, inadequate English skills, no phone or internet access, recent suicide attempt or medication changes.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive the TAILOR intervention, which includes Cognitive Behavioral Therapy, Motivational Interviewing, and voice- or video call-based assistance over 2 months
Follow-up
Participants are monitored for changes in sleep problems and suicidal ideation at 2 and 4 months post-randomization